RETINAL DISEASES ARE THE LEADING CAUSES OF BLINDNESS IN THE WESTERN WORLD
THE FUTURE IS HERE
RETMARKER'S AUTOMATED ARTIFICIAL INTELLIGENCE TECHNOLOGY AT THE SERVICE OF VISION LOSS PREVENTION GLOBALLY
LEARN MORE ABOUT
Highly reliable and affordable Diabetic Retinopathy Screening technology, available anywhere/everywhere.
DR Screening Providers
Predicts Diabetic Retinopathy sight-threatening complications by analyzing multiple retinal images taken over time.
Clinical Trials / Research
Simplified analysis and annotation of Age-Related Macular Degeneration lesions in retinal images.
Realizing that all diabetics should do a periodic eye check to control their risk of Diabetic Retinopathy, Retmarker developed a technology to be used in DR Screening initiatives. The rationale is that on top of the huge number of Diabetics worldwide, on average less than 10% of them will need referral to a doctor. This means there is a huge effort to screen everyone and identify the ones in need, a burden that could benefit easily from artificial intelligence technology as everyone now accepts.
Retmarker technology is certified as class IIa medical device in Europe and also approved in Australia. It has been tested over the years in many different conditions.
It was approved in the only independent study ever done to evaluate such technologies in real life conditions (study, led by A. Tufail from Moorfields Eye Hospital) with the best specificity – translates into burden reduction i.e. cost savings.
Retmarker’s initial development was a microaneurysm (the first lesion that occurs in Diabetic Retinopathy) detector and combined it with a co-registration algorithm (that allows to automatically overlap different images) to compute the Formation and Disappearance rates of microaneurysms. According to multiples studies, such rates are relevant to predict the risk of developing vision-threatening complications such as Diabetic Macular Edema and Proliferative Retinopathy.
This information is very useful for research activities and for patient enrolment in Clinical Trials as recognized by the European Medicine Agency (EMA) in 2015.
Age-Related Macular Degeneration
Retmarker image analysis capabilities were expanded to AMD lesions to support an Epidemiological Study. Very simple manual and preset annotations of Drusen (including confluence), Hypopigmentation, Hyperpigmentation, Geographic Atrophy and Exudative Lesions was added.
An additional module allowing multimodal comparison of annotations was also developed.
This software won an IT Award in London. In the end of 2019 a validation study was published in Nature: Eye.